Malignant Mesothelioma
71
5
5
45
Key Insights
Highlights
Success Rate
90% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
7.0%
5 terminated out of 71 trials
90.0%
+3.5% vs benchmark
10%
7 trials in Phase 3/4
16%
7 of 45 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 45 completed trials
Clinical Trials (71)
Rehabilitation by Effort for Patients With Advanced Bronchial Cancer
Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery
Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors
Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors
Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease
Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
Combination Chemotherapy With or Without Surgery & Chemoradiotherapy in Patients With Malignant Pleural Mesothelioma
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
A Study to Investigate 14C-bemcentinib in Healthy Male Subjects
Dendritic Cell Vaccination for Patients with Solid Tumors
Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors
A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
Tazemetostat Expanded Access Program for Adults With Solid Tumors
Observational Prospective Analysis of Biological Characteristics of Mesothelioma Patients
Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma
A Study of LY3023414 in Participants With Advanced Cancer
Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy
Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours